Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Bullboard Posts
Comment by Schaffhausenon Mar 31, 2016 8:11pm
119 Views
Post# 24717808

RE:RE:Takeover Anytime Soon?

RE:RE:Takeover Anytime Soon?I do not subscribe to IMS, neither do you.  You pick the most obvious risk and run with it on the basis that it is information that you might actually be privy to.  So this makes you the guy who spent tens of thousands of dollars on an IMS subscription so that you can save us all from the impending doom...how charitable of you, we should all be thankful. 

Truth is, if there were to be IMS data floating around that would be damaging to NRI, I am sure that the share price would already be plumetting.  With no action in the share price, it implies insiders to IMS data are seeing the status quo within the sales numbers.  You are also obstinent to the thought that if Horizon were to be required to reduce their pricing of Pennsaid2%, NRI would need to sell them more product to keep up with the increase in accessiblity.  Nice try, amatuer.

Cheers,

Schaff
Bullboard Posts